AlphAIalphai — Financial news for AI agents
Zacks CommentaryNOV 103 min read$KMDA

Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 10, 2025, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 11, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates — source image
Source · www.zacks.com
Decision brief

The 30-second read

$KMDANeutralMed
01

Why it matters

The earnings results could influence Kamada's stock price and investor sentiment, with potential ripple effects in the biotech sector.

02

Market read

High relevance for traders focusing on biotech stocks, especially around earnings season.

03

What to watch

Market reaction may be influenced by broader macroeconomic factors or sector-wide news unrelated to Kamada's fundamentals.

Timing: High, as earnings reports are time-sensitive and can influence immediate trading decisions.

Background

Kamada reported its Q3 2025 earnings, highlighting key financial metrics and comparing them to analyst estimates and previous year figures.

Company-level read

Ticker impact

$KMDANeutralMedium confidence
Context

The news pertains directly to Kamada's Q3 earnings report, making it highly relevant for trading decisions.

Expected impact

Potential short-term volatility with a slight upward bias if positive metrics dominate; however, mixed results may lead to sideways movement.

Evidence & confidence

Earnings reports often induce volatility; the mixed metrics create uncertainty, reducing confidence in a definitive directional move.

Market effects

Sector

The biotech sector may experience volatility based on Kamada's performance, influencing related stocks.

Regional

Potential impact on regional biotech markets, especially if Kamada's results differ significantly from peers.

Global

Limited, as Kamada is a regional player; global effects are minimal unless broader biotech trends are affected.

Counterpoint

What could challenge this read

The mixed earnings could indicate underlying operational issues, suggesting caution against bullish bets.

Key entities

  • Company
    Kamada

    Biotech firm specializing in plasma-derived therapies.

Read at source← All news

Related articles

AUG 12
$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

yahoo.com6 min
AUG 12
$KMDAHighAI 9/10

Kamada Ltd.: Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Gui

Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.

finanznachrichten.de6 min
JUL 20
$KMDAMedAI 8/10

Kamada jumps on $50m source plasma deal

Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.

globes.co.il2 min
AUG 12
$RKLBMed

U.S. Space Force Awards $615 Million for Space-Based Sensing and Targeting

The U.S. Space Force’s Space Systems Command awarded a second task order under its Space-Based Sensing and Targeting portfolio totaling $615 million, as part of three initial firm-fixed-price other transaction agreements. Awardees include Rocket Lab and STR LLC, plus a third unnamed company. The program aims to diversify vendors and develop airborne moving-target indicator capabilities for the Joint Force.

latimes.com4 min
AUG 12
$ORCLMed

Oracle employees face new layoff threat months after March job cuts

Oracle is preparing another round of layoffs, according to Business Insider citing internal documents and people familiar with the plans. The company cut about 21,000 jobs, or 13%, in fiscal 2026 ended May 31. Oracle says AI adoption may reduce workforce. It invested $55.7B in infrastructure, recorded $1.84B severance, and expects ~$70B capex plus ~$40B more funding.

americanbazaaronline.com5 min